Pelthos Therapeutics Inc. (PTHS) Current Ratio
- Current ratio · latest quarter: Value 1.98×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.98× | Current assets / current liabilities. $63.36M ÷ $31.96M ≈ 1.98× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 63.36M USD | Assets, Current |
| Current obligations | 31.96M USD | Liabilities, Current |
| Cash and equivalents | 24.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 14.48M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 21.47M USD | Inventory, Net |
| Payables | 5.85M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $63.36M | $31.96M | $24.19M | (m) | $14.48M | $21.47M | $5.85M | (m) | 1.98× |
| 2026-03-31 | $69.80M | $25.00M | $31.98M | (m) | $11.70M | $23.42M | $6.15M | (m) | 2.79× |
| 2025-12-31 | $53.41M | $25.99M | $17.97M | (m) | $8.86M | $23.57M | $2.99M | (m) | 2.05× |
| 2025-09-30 | $49.76M | $24.77M | $14.20M | (m) | (m) | $24.10M | $5.67M | (m) | 2.01× |
| 2025-06-30 | $822.85K | $7.32M | $100.00K | (m) | (m) | (m) | (m) | (m) | 0.11× |
| 2025-03-31 | $911.18K | $5.11M | (m) | (m) | (m) | (m) | (m) | (m) | 0.18× |
| 2024-12-31 | $1.37M | $4.08M | $513.00K | (m) | $0.00 | $0.00 | $1.90M | (m) | 0.34× |
| 2024-09-30 | $2.14M | $3.57M | (m) | (m) | (m) | (m) | (m) | (m) | 0.60× |
| 2024-06-30 | $2.60M | $2.79M | (m) | (m) | (m) | (m) | (m) | (m) | 0.93× |
| 2024-03-31 | $4.03M | $2.90M | $3.80M | (m) | (m) | (m) | (m) | (m) | 1.39× |
| 2023-12-31 | $96.39K | $6.54M | (m) | (m) | (m) | (m) | (m) | (m) | 0.01× |
| 2022-12-31 | $55.07K | $3.76M | $100.00K | (m) | (m) | (m) | (m) | (m) | 0.01× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |